Licensed to Cure for BioPharma

Dassault Systèmes has launched a new 'industry solution experience' for pharmaceutical and biotech companies – 'Licensed to Cure for BioPharma'.

Based on Dassault Systèmes’ 3DEexperience platform, the product is said to transform the way biotech and pharmaceutical companies manage product and process complexity by smoothing drug variation, enabling easier and faster expansion into new markets, while managing increasing regulatory requirements.

In an environment of expiring patents, more stringent regulations and increased development costs, companies are increasingly turning to drug variations to drive growth. With one active pharmaceutical ingredient yielding as many as 1,000 finished products, a biopharmaceutical company must have a business platform that not only manages product knowledge complexity, but also simultaneously drives collaboration, innovation, and compliancy.

Dassault says Licensed to Cure for BioPharma boosts compliance strategies and creates a structured approach to manage product and process complexity, resulting in faster delivery of product variations to new markets.


For functionality and security for externalised research, software providers have turned to the cloud, writes Sophia Ktori


Robert Roe investigates the growth in cloud technology which is being driven by scientific, engineering and HPC workflows through application specific hardware


Robert Roe learns that the NASA advanced supercomputing division (NAS) is optimising energy efficiency and water usage to maximise the facility’s potential to deliver computing services to its user community


Robert Roe investigates the use of technologies in HPC that could help shape the design of future supercomputers